Mechanisms of Renal Cell Apoptosis Induced by Cyclosporine A: A Systematic Review of in vitro Studies

Zheng Xiao$^a$ Chengwen Li$^a$ Juan Shan$^a$ Lei Luo$^a$ Li Feng$^a$ Jun Lu$^a$
Shengfu Li$^a$ Dan Long$^a$ Youping Li$^{a,b}$

$^a$Key Laboratory of Transplant Engineering and Immunology of the Health Ministry of China, West China Hospital, Sichuan University, and $^b$Chinese Evidence-Based Medicine Centre, Chengdu, PR China

**Key Words**
Cyclosporine A · Apoptotic mechanisms · Renal cells · Chronic cyclosporine A nephrotoxicity

**Abstract**
**Background:** Chronic cyclosporine A (CsA) nephrotoxicity (CCN) is a major cause of chronic renal dysfunction and has no effective clinical interventions yet. **Objective:** To reveal the mechanisms of renal cell apoptosis in CCN, we analyzed all in vitro studies of such mechanisms. **Methods:** We collected all in vitro studies about the mechanisms of renal cell apoptosis induced by CsA in Medline (1966 to July 2010), Embase (1980 to July 2010) and ISI (1986 to July 2010), evaluated their quality according to in vitro standards and extracted data following the PICOS principles and synthesized the data. **Results:** First, CsA could upregulate Fas and Fas-L expression, increase FADD and apoptosis enzymes (caspase-2, -3, -4, -7, -8, -9 and -10) and downregulate the Bcl-2 and Bcl-xL. Second, CsA could induce oxidative stress and damage the antioxidant defense system. Third, CsA could increase the expression of HERP, GRP78 and CHOP. Fourth, CsA could induce renal cell apoptosis and increase their iNOS and p53 expression in cultured cells. **Conclusions:** At least four pathways are involved in renal cell apoptosis induced by CsA in different cell species. Caspases might be their final common pathway in vitro. They might all provide potential points for interventions, but these need to be confirmed in vivo.

**Introduction**
All immunosuppressants and surgical techniques have obviously increased the short-term graft survival rate, but not the long-term graft survival rate. Therefore, how to improve the long-term survival rate/life quality of graft and recipient becomes a critical issue. Current strong immunosuppressants can effectively control acute rejection and protect the graft from injury by suppressing the immune cell activation, proliferation differentiation and migration. However, most also have strong toxicity to normal cells that seriously decrease the long-term graft/patient survival rate and their life quality.

Until now, renal transplantation is still the most common therapeutic option for patients with end-stage renal
disease. Their short-term results have been excellent, but long-term graft survivals have not improved substantially in recent times. Cyclosporine A (CsA) is widely used for organ transplantation and autoimmune disorders [1, 2], but it was proven that long-term use of CsA could lead to chronic CsA nephrotoxicity (CCN). Also, it became an important cause of chronic renal dysfunction (CRD) that is the most important cause of graft loss [3–8]. Long-term use of CsA could cause CCN through directly injuring renal cells [9, 10], activating the renin-angiotensin-aldosterone system (RAS) [11, 12] and upregulating the transforming growth factor-β (TGF-β) [13–15], etc. All these lead to renal cell apoptosis and finally to CRD. Therefore, renal cell apoptosis might be one of the primary causes in CRD [3]. Up to now, its apoptotic mechanism is not clear, and there are no effective clinical interventions.

To reveal the mechanisms and provide new ideas for prevention, intervention and further studies of CRD, we systematically evaluated the studies for their apoptotic mechanisms and interventions of CsA-induced renal cell apoptosis in vitro and in vivo. Our systematic reviews (SR) involved: (1) mechanisms of renal cell apoptosis induced by CsA in vitro, (2) mechanisms of renal cell apoptosis induced by CsA in animals, and (3) interventions and their mechanisms of renal cell apoptosis in CCN. The mechanisms of renal cell apoptosis induced by CsA in vitro are reported here.

**Methods**

**Search Strategy**

Two reviewers (Z.X. and C.L.) independently searched potentially relevant articles in the databases of Medline (1966 to July 2010), Embase (1974 to July 2010) and ISI (1986 to July 2010) using the search strategy ((Nephrotoxicity and (Cyclosporine A or CsA or CyA or Cyclosporine)) and Apoptosis) or ((Cyclosporine A or CsA or CyA or Cyclosporine) and (Renal tubular epithelial cell or Renal cells) and Apoptosis). All articles were collected without language restrictions.

**Included/Excluded Criteria**

We included all in vitro studies about the mechanisms of renal cell apoptosis induced by CsA (no limitation of research design and language) and excluded the duplicated articles, meeting abstracts and reviews without specific data.

**Evaluation Standards**

The quality of all articles was evaluated according to in vitro standards referencing CRH and the EBM Evidence Pyramid [16] defined by ourselves in the following because there is no generally accepted evaluation standard for basic research studies at present.

<table>
<thead>
<tr>
<th>Grade</th>
<th>In vitro</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Systematic reviews (i.e. meta-analyses) of studies in vitro</td>
</tr>
<tr>
<td>B</td>
<td>With comparable baseline</td>
</tr>
<tr>
<td>C</td>
<td>Baseline unknown</td>
</tr>
<tr>
<td>D</td>
<td>No comparable baseline</td>
</tr>
</tbody>
</table>

**Selection and Evaluation of Articles**

Two reviewers (Z.X. and C.L.) independently selected and evaluated articles according to in vitro standards defined by ourselves. Any disagreements were resolved by discussion with each other or with Y. Li.

**Data Extraction and Synthesis**

All included studies were in vitro studies. They were classified into two groups as characteristics and mechanisms of renal cell apoptosis. Because of poor homogeneity, we synthesized the data by descriptive methods. After reviewing all articles, we designed data extraction tables according to research themes and extracted the experimental data following PICOS, which are cells (P), Interventions (I), Control study (C), Outcomes (O) and Study Design (S) of studies and then synthesized the data.

**Results**

**Search Results**

Overall, 454 potential articles were identified. On the initial screen, 97 full-text articles were retrieved and assessed for eligibility (fig. 1). Finally, 19 studies met the inclusion criteria.

**Quality of Studies**

All 19 in vitro studies had a comparable baseline and we evaluated them as grade B. Their quality grades were shown in data extraction tables.

**Main Characteristics of CsA-Induced Renal Cell Apoptosis in vitro**

Twelve experiments on CsA-induced renal cell apoptosis in vitro from 19 articles were included (shown in table 1). Renal tubular epithelial cells (human, pig, canine and mouse), vascular endothelial cell (human and mouse) and human mesangial cells were used in these experiments. The apoptotic rate was detected by the TUNEL method, FITC-annexin binding and DNA fragments, etc. CsA could dramatically induce their apoptosis in a time- and dose-dependent manner when co-cultured with different renal cells. There was no difference of CsA-induced apoptosis in different human renal cell strains.
Table 1. Main characteristics of CsA-induced renal cell apoptosis in vitro

<table>
<thead>
<tr>
<th>Reference (first author)</th>
<th>P cells/species</th>
<th>I CsA dose</th>
<th>T</th>
<th>C</th>
<th>O†</th>
<th>S</th>
<th>QG</th>
</tr>
</thead>
<tbody>
<tr>
<td>Esposito [17]</td>
<td>HEC, HK-2 (human)</td>
<td>800 ng/ml</td>
<td>24 h</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>B</td>
</tr>
<tr>
<td>Amore [18]</td>
<td>cells² (human)</td>
<td>0.1–1 μg/ml</td>
<td>4–24 h</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>B</td>
</tr>
<tr>
<td>Daly [19]</td>
<td>HK-2 (human)</td>
<td>0.2–80 μM</td>
<td>24 h</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>B</td>
</tr>
<tr>
<td>Jo [20]</td>
<td>HK-2 (human)</td>
<td>1,000 ng/ml</td>
<td>24 h</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>B</td>
</tr>
<tr>
<td>De Arriba [21]</td>
<td>LLC-PK1 (pig)</td>
<td>1 μM</td>
<td>24 h</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>B</td>
</tr>
<tr>
<td>Perez [22]</td>
<td>PTECs (pig)</td>
<td>1–1,000 ng/ml</td>
<td>48 h</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>B</td>
</tr>
<tr>
<td>Healy [9]</td>
<td>LLC-PK1 (pig)</td>
<td>4.2 nM</td>
<td>24 h</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>B</td>
</tr>
<tr>
<td>Jeon [23]</td>
<td>MDCK (canine)</td>
<td>10 μM</td>
<td>48 h</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>B</td>
</tr>
<tr>
<td>Cheng [24]</td>
<td>MDCK (canine)</td>
<td>20 μM</td>
<td>24 h</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>B</td>
</tr>
<tr>
<td>Justo [25]</td>
<td>MCT (mice)</td>
<td>10 μg/ml</td>
<td>24 h</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>B</td>
</tr>
<tr>
<td>Conti [26]</td>
<td>EC (mice)</td>
<td>0.25–2 μg/ml</td>
<td>12 h</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>B</td>
</tr>
<tr>
<td>Ortiz [27]</td>
<td>MCT (mice)</td>
<td>0.1–15 μg/ml</td>
<td>24–72 h</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>B</td>
</tr>
</tbody>
</table>

Cells (P): Proximal tubule epithelial cells (human, pig, canine and mice), vascular endothelial cells (human and mice), human mesangial cells; Interventions (I): CsA (different doses); Time (T): co-cultured times; Control (C): normal culture medium; Outcomes (O): apoptosis of tubular, endothelial cells or mesangial cells; Study (S): in vitro; QG: quality grade. ✓ = Yes; † = increased.

1 Citation of included articles; different shading shows different cells.

2 Human mesangial cells, human tubular cells, human umbilical vein endothelial cells, or murine endothelial cells; human endothelial cells (HECs); human renal tubular epithelial cells (HK-2); porcine renal endothelial cell line LLC-PK1; primary cultures of pig kidney proximal tubule epithelial cells (PTECs); Madin-Darby canine kidney (MDCK) tubular epithelial cells; murine proximal tubular epithelial MCT cells; murine endothelial cell line (EC).

Fig. 1. Articles retrieved and assessed for eligibility.
CsA 0.1–1 μg/ml could induce the human cell apoptosis (HK-2s, HECs and human mesangial cells) after about 24 h in vitro. There was a big difference of the concentration and co-culture time which CsA induced in renal cell apoptosis in other animal cell strains.

Mechanisms of CsA-Induced Renal Cell Apoptosis in vitro

Twenty-two experiments from 19 articles about the mechanisms of renal cell apoptosis induced by CsA are listed in tables 2–5. There were four apoptotic pathways, namely Fas/Fas-L, mitochondrial, endoplasmic reticulum (ER), and NO-related pathway. They synergistically mediated cell apoptosis.

Fas/Fas-L Pathway

All 7 studies were included and their quality as score A shown in table 2. CsA induced cell apoptosis in a time- and dose-dependent manner when co-cultured with renal tubular epithelium of human/pig/canine and mice for 24 h. It upregulated expression of Fas and Fas-L in 4 studies, increased the FADD and cleavage product of Fas/Fas-L pathway.

Mitochondrial pathway

Mitochondrial dysfunction and oxidative stress, Cyt-c release, translocation of Bax protein

Endoplasmic reticulum pathway

Endoplasmic reticulum response gene (GRP78, PDI, CHOP), loss of mitochondrial membrane potential (uncertain)

NO-related pathway

p53

Final common pathway

Caspase-8, -9, -12

Caspase-3, -6

Renal cell apoptosis
PARP in 2 studies, downregulated anti-apoptotic factors (Bcl-2 and Bcl-xL) with the cytochrome c release to cytosol and the translocation of Bax to the mitochondria, which led to the imbalance of Bcl/Bax in 3 studies. The activity of caspases (caspase-2, -3, -4, -7, -8, -9 and -10) in co-cultured cells was also increased in 4 studies. Co-cultured with rat mesangial cells, CsA increased the cleavage product of PARP, downregulated the anti-apoptotic protein (Bcl-2) with the translocation of Bax to the mitochondria. The activity of the apoptosis enzymes (caspase-3 and -6) was increased in CsA-treated rat mesangial cells.

Mitochondrial Pathway

All 9 studies were included and their quality as score A shown in table 3. Different dosages of CsA significantly induced cell apoptosis when co-cultured with renal tubular epithelial cells of pig/canine and mice. CsA increased ROS in a dose-dependent manner. It induced mitochondrial dysfunction and oxidative stress in cocultured cells in 4 studies. It injured the antioxidant defense system, of which the NADPH and catalase were dramatically decreased in 2 studies. It caused Bax migration to mitochondria and also released cytochrome c into cytosol in 3 studies. It downregulated anti-apoptotic proteins (Bcl-2 and Bcl-xL) in 4 studies and increased the activity of caspase-2, -3, -6, and -9 in 4 studies.

Endoplasmic Reticulum Pathway

Studies and their quality as score A were included and are shown in table 4. CsA increased the expression of various genes mediating cell death during ER stress, e.g. GRP78, CHOP and HERP mRNA expression early, when co-cultured with human renal tubular epithelial cells. The activity of caspase-3 and -7 was also increased in PTEC cells treated with CsA.

Nitric Oxide-Related Pathway

All 4 studies were included and their quality as score A shown in table 5. CsA could increase the nitric oxide (NO) in culture, when co-cultured with HK-2. When co-cultured with human mesangial cells, HK-2, HUVECs, or ECs within 12–24 h, CsA significantly increased the protein expression of inducible nitric oxide synthase (iNOS) and p53 and the iNOS activity in all cell lines. When co-cultured with rat mesangial cells or murine endothelial cells, CsA could upregulate p53 and increase the activity of caspase-3 and -6.

Discussion

The molecular mechanisms by which cyclosporine induced chronic nephrotoxicity remain poorly understood. To reveal the mechanisms of renal cell apoptosis induced by CsA and provide new ideas for prevention, intervention and further studies of CRD, we systemati-
Mechanisms of Renal Cell Apoptosis Induced by Cyclosporine A

Nephrotoxicity is the major problem in the use of CsA. Our SR results demonstrated that CsA 0.1–1 μg/ml could induce human cell apoptosis (HK-2s, HECs and human mesangial cells) after about 24 h in vitro. CsA induced renal cell apoptosis in other animal cell strains, but there was a big difference of its concentration and co-culture time. This shows that it is dangerous when the serum CsA level is >0.1 μg/ml. Maintenance of CsA levels at the lower limits of the therapeutic range is desirable. There are more differences of serum CsA levels in different reports. Tan [36] reported that the optimal C2 (2 h peak concentration) target level of Chinese renal transplantation recipients was 1,250–1,500 ng/ml for the first 3 months post-transplantation. Wada et al. [37] reported that mean C2 values >1,000 ng/ml were obtained in patients with no rejection at 1 and 12 months after transplantation in Japanese heart transplant patients. However, renal impairment may occur. Belitsky et al. [38] recommended that optimal C2 target levels were 1,700 ng/ml at 0–6 months and 1,200 ng/ml at 6–12 months in kidney transplant patients. In all, serum CsA levels are >0.1 μg/ml. Many studies confirmed that long-term use of CsA after renal transplantation could induce CCN [3–8]. Therefore, we think that CsA-induced renal cell apoptosis might be one of the primary causes in CRD. Its detailed mechanism becomes even more important for preventing CRD.

To reveal the mechanisms of renal cell apoptosis induced by CsA in vitro, we systematically analyzed all the relevant articles and collected 22 experiments about the mechanisms of renal cell apoptosis induced by CsA. Their apoptotic mechanisms are complex. At least four apoptotic pathways mediate renal cell apoptosis in vitro including the Fas/Fas-L, mitochondrial, ER and NO-related apoptotic pathway and synergistically mediated cell apoptosis (fig. 2).

Table 4. Endoplasmic reticulum pathway

<table>
<thead>
<tr>
<th>Reference (first author)</th>
<th>P cells/species</th>
<th>I CsA</th>
<th>C T</th>
<th>O1 O2 O3</th>
<th>S QG</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pallet [34]</td>
<td>HRECs (human)</td>
<td>6 μM</td>
<td>0–24 h</td>
<td>√</td>
<td>GRP78, PDI, CHOP, HERP</td>
</tr>
<tr>
<td>Hortelano [35]</td>
<td>PTECs (pig)</td>
<td>10 nM</td>
<td>24–72 h</td>
<td>√</td>
<td>−</td>
</tr>
</tbody>
</table>

P: Proximal tubule epithelial cells (human and pig); I: CsA (different doses); T: co-cultured times; C: normal media; O: O1: GRP78), C/EBP homology protein (CHOP) (†); O2: ER cisternae dilatations (†); O3: caspases (†); S: in vitro; QG: quality grade. √ = Yes; − = no. † = Increased. HRECs = Human renal tubular cells.

1 Citation of included articles; different shading shows PICOS.

Table 5. NO-related pathway

<table>
<thead>
<tr>
<th>Reference (first author)</th>
<th>P cells/species</th>
<th>I CsA</th>
<th>C T</th>
<th>O1† O2† O3† O4†</th>
<th>S</th>
<th>QG</th>
</tr>
</thead>
<tbody>
<tr>
<td>Esposito [17]</td>
<td>HEC, HK-2 (human)</td>
<td>0.05–0.8 μg/ml</td>
<td>24 h</td>
<td>√</td>
<td>NO</td>
<td>−</td>
</tr>
<tr>
<td>Amore [18]</td>
<td>cells² (human)</td>
<td>0.1–1 μg/ml</td>
<td>4–24 h</td>
<td>√</td>
<td>iNOS P53</td>
<td>−</td>
</tr>
<tr>
<td>Conti [26]</td>
<td>EC (mice)</td>
<td>0.25–2 μg/ml</td>
<td>12 h</td>
<td>√</td>
<td>−</td>
<td>P53</td>
</tr>
<tr>
<td>Han [29]</td>
<td>RMCs (rat)</td>
<td>0.1–40 μM</td>
<td>24 h</td>
<td>√</td>
<td>−</td>
<td>P53 caspase-3, -7</td>
</tr>
</tbody>
</table>

P: Proximal tubule epithelial cells (human), RMCs and vascular endothelial cells (mice); I: CsA (different doses); T: co-cultured times; C: normal media; O: O1: nitric oxide (†); O2: pro-apoptotic factors (†); O3: caspases; O4: apoptosis (†); S: in vitro; QG: quality grade. √ = Yes; − = no. † = Increased.

2 Human mesangial cells, human tubular cells, human umbilical vein endothelial cells, or murine endothelial cells.

1 Citation of included articles; different shading shows PICOS.

Optimal C2 target levels were 1,700 ng/ml at 0–6 months and 1,200 ng/ml at 6–12 months in kidney transplant patients. In all, serum CsA levels are >0.1 μg/ml. Many studies confirmed that long-term use of CsA after renal transplantation could induce CCN [3–8]. Therefore, we think that CsA-induced renal cell apoptosis might be one of the primary causes in CRD. Its detailed mechanism becomes even more important for preventing CRD.

To reveal the mechanisms of renal cell apoptosis induced by CsA in vitro, we systematically analyzed all the relevant articles and collected 22 experiments about the mechanisms of renal cell apoptosis induced by CsA. Their apoptotic mechanisms are complex. At least four apoptotic pathways mediate renal cell apoptosis in vitro including the Fas/Fas-L, mitochondrial, ER and NO-related apoptotic pathway and synergistically mediated cell apoptosis (fig. 2).

Our SR results showed that CsA could significantly increase the Fas/Fas-L, FADD and PARP, induce mitochondrial dysfunction and oxidative stress and injure the
antioxidant defense system. It also caused Bax migration to the mitochondria, released cytochrome c into cytosol, downregulated anti-apoptotic proteins (Bcl-2 and Bcl-xL) and increased the activity of caspase-2, -3, -4, -7, -8, -9 and -10. They finally activated caspase-9 and -3 which mediate cell apoptosis [39–42]. All show that CsA can induce renal cell apoptosis through the Fas/Fas-L pathway and mitochondrial pathway with sufficient evidence.

ER stress is an adaptive response to many external stimuli such as oxidative stress, or exposure to many chemicals [43–46]. The ER stress markers could present important roles in cell apoptosis such as BIP, GRP78, CHOP, HERP, etc. The ER stress markers BIP/GRP78 were increased in CsA-treated renal allograft of kidney transplant recipients [47]. Our SR results showed that CsA could significantly increase the GRP78, CHOP and HERP mRNA early expression and activate caspase-3 and -7 when co-cultured with renal cells for 24–72 h. Gupta et al. [48] confirmed that apoptotic factors (caspase-9 and -2, Bcl-2) and loss of mitochondrial membrane potential showed important roles in ER stress-induced apoptosis [48]. However, they found that CsA could attenuate the loss of mitochondrial transmembrane potential (ΔΨm) induced by ER stress. In another study, Bian et al. [49] found that caspase-4 was dually involved in inflammatory and ER stress-induced apoptotic responses in human retinal pigment epithelial cells. Therefore, all the evidence has shown that CsA might induce renal cell apoptosis through the ER pathway in vitro. Therefore, whether CsA induces renal cell apoptosis by the ER pathway needs to be confirmed by further studies.

NO is an important messenger molecule involved in both beneficial and harmful processes within the mammalian body [50]. Our SR results showed that CsA could induce apoptosis of various renal cell lines by enhancing NO synthesis, and this effect was mediated by the induction of iNOS via p53 and the activation of caspase-3 and -6 [18, 29, 51]. Finally, these might contribute to the acellular fibrosis characteristic of CCN. NO and the expression of endothelial (eNOS) and inducible (iNOS) isoforms of NOS were recognized as important mediators of physiological and pathological processes of renal injuries such as renal ischemia/reperfusion [52], partial or complete unilateral ureteral obstruction [53], chronic renal disease [54] and hydronephrosis [55], etc. NO and iNOS could contribute to renal injury through apoptosis of tubular epithelial cells [56]. Activation of caspase-8 plays a central role in NO-induced apoptosis [56]. Therefore, we think that NO-related pathway is an important pathway of CsA-induced renal cell apoptosis.

The four pathways shown in this study might provide four points for interventions. For example, can one intervention inhibit apoptosis by blocking four pathways simultaneously? Four pathways simultaneously are hardly blocked by one intervention. Or do they have a common pathway? All the above evidence shows that CsA can activate caspases through four pathways in co-cultured cells and finally mediate cell apoptosis, then these caspases might be the ultimate intersection of these apoptotic pathways and their final common pathway. If so, it will be the new target for intervention in CNN.

This study demonstrated that at least four pathways mediated CsA-induced renal cell apoptosis with different cells species in vitro. Caspases might be their final common pathway in vitro. They might all provide potential point for interventions, but these need to be confirmed in vivo. We will report the mechanisms of renal cell apoptosis induced by CsA in vivo in another SR.

Appendix

I. Search terms: Nephrotoxicity, Cyclosporine A, CsA, CyA, Cyclosporine, Renal tubular epithelial cell, Renal cells and Apoptosis.

II. Search strategy: First: (Nephrotoxicity and (Cyclosporine A or CsA or CyA or Cyclosporine)) and Apoptosis. Second: Cyclosporine A or CsA or CyA or Cyclosporine) and (Renal tubular epithelial cell or Renal cells) and Apoptosis). Third: First or Second.

III. Search Members: Z. Xiao and C. Li.

IV. Databases and search time: Medline (1966 to July 2010), Embase (1974 to July 2010) and ISI (1986 to July 2010).

V. Research results: Medline (n = 99), Embase (n = 171) and ISI (n = 184).

Acknowledgment

This work was funded by grants from the National 973 Project Foundation of China, No. 2009CB522401.

Disclosure Statement

The authors have no conflicts of interest to declare.
References

4. Magnasco A, Rossi A, Catarsi P, Gusmano R, Induced by Cyclosporine A

Mechanisms of Renal Cell Apoptosis
Induced by Cyclosporine A

Am J Nephrol 2011; 33:558–566

Cheng CH, Hsieh CL, Shu KH, Chen YL, Chen HC: Effect of calcium channel antagon


Conti G, Amore A, Cirina P, Gianoglio B, Pe


De Arriba G, de Hornedo JP, Rubio SR, Fern


Amore A, Emancipator SN, Cirina P, Conti G, Ricotti E, Bagheri N, Coppo R: Nitric ox

OT, Torfing O, Plana M, Meseguer A, Itarte E: Phosphoinositide 3-kinase inhibitors prot

Fornoni A, Cornacchia F, Bellotti N, Fasoli G, Foschi A, Mazzucchielli I, Mazzullo T, S


Jo SK, Lee SY, Han SY, Cha DR, Cho WY, Kim HK, Won NH: Alpha-melanocyte stimulate


De Arriba G, de Hornedo JP, Rubio SR, Fern


Lonfoni B, Boschi E, Demontis GC, Ratto GM, Mosca F: Apoptosis and adaptive respon


Ivor Gaspari F, Perico N, Gotti E, Bertani T, Re


Fornoni A, Li H, Foschi A, Striker GE, Striker L: Hepatocyte growth factor but not insul

De Arriba G, de Hornedo JP, Rubio SR, Fer


Amore A, Emancipator SN, Cirina P, Conti G, Ricotti E, Bagheri N, Coppo R: Nitric ox

OT, Torfing O, Plana M, Meseguer A, Itarte E: Phosphoinositide 3-kinase inhibitors prot

Fornoni A, Li H, Foschi A, Striker GE, Striker L: Hepatocyte growth factor but not insul

De Arriba G, de Hornedo JP, Rubio SR, Fer


Amore A, Emancipator SN, Cirina P, Conti G, Ricotti E, Bagheri N, Coppo R: Nitric ox

OT, Torfing O, Plana M, Meseguer A, Itarte E: Phosphoinositide 3-kinase inhibitors prot

Fornoni A, Li H, Foschi A, Striker GE, Striker L: Hepatocyte growth factor but not insul

De Arriba G, de Hornedo JP, Rubio SR, Fer


Amore A, Emancipator SN, Cirina P, Conti G, Ricotti E, Bagheri N, Coppo R: Nitric ox

OT, Torfing O, Plana M, Meseguer A, Itarte E: Phosphoinositide 3-kinase inhibitors prot

Fornoni A, Li H, Foschi A, Striker GE, Striker L: Hepatocyte growth factor but not insul

De Arriba G, de Hornedo JP, Rubio SR, Fer


Amore A, Emancipator SN, Cirina P, Conti G, Ricotti E, Bagheri N, Coppo R: Nitric ox

OT, Torfing O, Plana M, Meseguer A, Itarte E: Phosphoinositide 3-kinase inhibitors prot

Fornoni A, Li H, Foschi A, Striker GE, Striker L: Hepatocyte growth factor but not insul

De Arriba G, de Hornedo JP, Rubio SR, Fer


Amore A, Emancipator SN, Cirina P, Conti G, Ricotti E, Bagheri N, Coppo R: Nitric ox

OT, Torfing O, Plana M, Meseguer A, Itarte E: Phosphoinositide 3-kinase inhibitors prot

Fornoni A, Li H, Foschi A, Striker GE, Striker L: Hepatocyte growth factor but not insul

De Arriba G, de Hornedo JP, Rubio SR, Fer


Amore A, Emancipator SN, Cirina P, Conti G, Ricotti E, Bagheri N, Coppo R: Nitric ox

OT, Torfing O, Plana M, Meseguer A, Itarte E: Phosphoinositide 3-kinase inhibitors prot

Fornoni A, Li H, Foschi A, Striker GE, Striker L: Hepatocyte growth factor but not insul

De Arriba G, de Hornedo JP, Rubio SR, Fer


Amore A, Emancipator SN, Cirina P, Conti G, Ricotti E, Bagheri N, Coppo R: Nitric ox


